Skip to main content
Erschienen in: Virchows Archiv 4/2012

01.10.2012 | Original Article

Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy

verfasst von: Amber M. D’Souza, Kamal S. Pohar, Tahir Arif, Susan Geyer, Debra L. Zynger

Erschienen in: Virchows Archiv | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

A range of studies have analyzed prognostic factors in bladder cancer. However, prior cohorts have included heterogeneous pT classification at biopsy and others were derived from large, multi-institutional clinical trials over the span of many years. Our objective was to analyze prognostic factors in a recent radical cystectomy (RC) cohort at a single institution and evaluate outcomes based on current practice patterns. A retrospective analysis of overall survival (OS) was conducted on 180 RC patients with biopsy proven pT2 disease between 2007–2010. Increasing pT classification was a negative predictor of survival. pT was grouped into three categories with pT0/a/is/1/2a surviving longer than pT2b/3a/3b, and pT4 having the worst prognosis. Subclassifying pT2 and pT3 showed no statistically significant difference in survival. Lymphovascular invasion (LVI) and node positivity correlated with decreased OS. Patients treated with neoadjuvant chemotherapy (NAC) had a higher incidence of pT0, yet pN1+ was more common and NAC was not associated with improved OS. This investigation provides reference OS values for patients with pathologically diagnosed muscle-invasive bladder cancer based on current medical guidelines outside the context of a clinical trial. pT4 was the strongest negative predictor of survival, followed by pN1+, the group pT2b/3a/3b, and presence of LVI. NAC patients were noted to have a higher frequency of low pT classification, yet more frequent node positivity, suggesting that pT classification in NAC patients may not accurately reflect remaining tumor burden.
Literatur
3.
Zurück zum Zitat Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866PubMedCrossRef Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866PubMedCrossRef
5.
Zurück zum Zitat Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055PubMed Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055PubMed
6.
Zurück zum Zitat von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077PubMed von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077PubMed
7.
Zurück zum Zitat Canter D, Long C, Kutikov A, Plimack E et al (2011) Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 107:58–62PubMedCrossRef Canter D, Long C, Kutikov A, Plimack E et al (2011) Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 107:58–62PubMedCrossRef
8.
Zurück zum Zitat Edge SB, Byrd DR, Comptom CC (2010) American Joint Committee on Cancer. AJCC Cancer Staging Manual, Seventh Edition. Springer, New York, pp 497–502 Edge SB, Byrd DR, Comptom CC (2010) American Joint Committee on Cancer. AJCC Cancer Staging Manual, Seventh Edition. Springer, New York, pp 497–502
9.
Zurück zum Zitat Fedeli U, Fedewa SA, Ward EM (2011) Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 185:72–78PubMedCrossRef Fedeli U, Fedewa SA, Ward EM (2011) Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 185:72–78PubMedCrossRef
10.
Zurück zum Zitat Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMed Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMed
11.
Zurück zum Zitat Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690–696PubMedCrossRef Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690–696PubMedCrossRef
12.
Zurück zum Zitat Weight CJ, Garcia JA, Hansel DE et al (2009) Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer 115:792–799PubMedCrossRef Weight CJ, Garcia JA, Hansel DE et al (2009) Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer 115:792–799PubMedCrossRef
13.
Zurück zum Zitat Manoharan M, Katkoori D, Kishore TA et al (2009) Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed. BJU Int 104:1646–1649PubMedCrossRef Manoharan M, Katkoori D, Kishore TA et al (2009) Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed. BJU Int 104:1646–1649PubMedCrossRef
14.
Zurück zum Zitat Pollack A, Zagars GK, Cole CJ et al (1995) The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 154:2059–2063PubMedCrossRef Pollack A, Zagars GK, Cole CJ et al (1995) The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 154:2059–2063PubMedCrossRef
15.
Zurück zum Zitat Honma I, Masumori N, Sato E et al (2004) Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 64:744–748PubMedCrossRef Honma I, Masumori N, Sato E et al (2004) Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 64:744–748PubMedCrossRef
16.
Zurück zum Zitat Tilki D, Svatek RS, Karakiewicz PI et al (2010) pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol 184:470–474PubMedCrossRef Tilki D, Svatek RS, Karakiewicz PI et al (2010) pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol 184:470–474PubMedCrossRef
17.
Zurück zum Zitat Sonpavde G, Khan MM, Svatek RS et al (2011) Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 185:1216–1221PubMedCrossRef Sonpavde G, Khan MM, Svatek RS et al (2011) Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 185:1216–1221PubMedCrossRef
18.
Zurück zum Zitat Yu RJ, Stein JP, Cai J et al (2006) Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 176:493–8PubMedCrossRef Yu RJ, Stein JP, Cai J et al (2006) Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 176:493–8PubMedCrossRef
19.
Zurück zum Zitat Boudreaux KJ Jr, Clark PE, Lowrance WT et al (2009) Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 181:540–545PubMedCrossRef Boudreaux KJ Jr, Clark PE, Lowrance WT et al (2009) Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 181:540–545PubMedCrossRef
20.
Zurück zum Zitat Tilki D, Svatek RS, Novara G et al (2010) Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol 184:888–894PubMedCrossRef Tilki D, Svatek RS, Novara G et al (2010) Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol 184:888–894PubMedCrossRef
21.
Zurück zum Zitat Amling CL, Thrasher JB, Frazier HA et al (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31–35PubMed Amling CL, Thrasher JB, Frazier HA et al (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31–35PubMed
22.
Zurück zum Zitat Ghoneim MA, El-Mekresh MM, Mokhtar AA et al (2000) A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 85:811–816PubMedCrossRef Ghoneim MA, El-Mekresh MM, Mokhtar AA et al (2000) A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 85:811–816PubMedCrossRef
23.
Zurück zum Zitat Abdel-Latif M, Abol-Enein H, El-Baz M et al (2004) Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol 172:85–89PubMedCrossRef Abdel-Latif M, Abol-Enein H, El-Baz M et al (2004) Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol 172:85–89PubMedCrossRef
24.
Zurück zum Zitat Lotan Y, Gupta A, Shariat SF et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23:6533–6539PubMedCrossRef Lotan Y, Gupta A, Shariat SF et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23:6533–6539PubMedCrossRef
25.
Zurück zum Zitat Quek ML, Stein JP, Nichols PW et al (2005) Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174:103–106PubMedCrossRef Quek ML, Stein JP, Nichols PW et al (2005) Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174:103–106PubMedCrossRef
26.
Zurück zum Zitat Shariat SF, Svatek RS, Tilki D et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402–1412PubMedCrossRef Shariat SF, Svatek RS, Tilki D et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402–1412PubMedCrossRef
27.
Zurück zum Zitat Yang XJ, Lecksell K, Eptsein JI (1999) Can immunohistochemistry enhance the detection of micrometasasis in pelvic lymph nodes from patients with high-grade urothelial carcinoma of the bladder? Am J Clin Pathol 112:649–653PubMed Yang XJ, Lecksell K, Eptsein JI (1999) Can immunohistochemistry enhance the detection of micrometasasis in pelvic lymph nodes from patients with high-grade urothelial carcinoma of the bladder? Am J Clin Pathol 112:649–653PubMed
28.
Zurück zum Zitat International Collaboration of Trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540CrossRef International Collaboration of Trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540CrossRef
29.
Zurück zum Zitat Sonpavde G, Goldman BH, Speights VO et al (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104–4019PubMedCrossRef Sonpavde G, Goldman BH, Speights VO et al (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104–4019PubMedCrossRef
30.
Zurück zum Zitat Sherif A, Rintala E, Mestad O et al (2002) Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425PubMedCrossRef Sherif A, Rintala E, Mestad O et al (2002) Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425PubMedCrossRef
31.
Zurück zum Zitat Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927–1934CrossRef Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927–1934CrossRef
32.
Zurück zum Zitat Sherif A, Holmberg L, Rintala E et al (2004) Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45:297–303PubMedCrossRef Sherif A, Holmberg L, Rintala E et al (2004) Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45:297–303PubMedCrossRef
33.
Zurück zum Zitat Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–205CrossRef Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–205CrossRef
34.
Zurück zum Zitat International Collaboration of Trialists (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177CrossRef International Collaboration of Trialists (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177CrossRef
Metadaten
Titel
Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy
verfasst von
Amber M. D’Souza
Kamal S. Pohar
Tahir Arif
Susan Geyer
Debra L. Zynger
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 4/2012
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-012-1249-4

Weitere Artikel der Ausgabe 4/2012

Virchows Archiv 4/2012 Zur Ausgabe

Neu im Fachgebiet Pathologie